Compare BTOC & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTOC | CLRB |
|---|---|---|
| Founded | 2020 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 12.0M |
| IPO Year | 2023 | 2008 |
| Metric | BTOC | CLRB |
|---|---|---|
| Price | $0.26 | $2.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $10.00 |
| AVG Volume (30 Days) | 48.0K | ★ 70.0K |
| Earning Date | 05-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $190,408,258.00 | N/A |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $14.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $0.23 | $2.20 |
| 52 Week High | $1.77 | $6.52 |
| Indicator | BTOC | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 39.78 |
| Support Level | $0.26 | N/A |
| Resistance Level | $0.33 | $3.03 |
| Average True Range (ATR) | 0.03 | 0.16 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 32.77 | 15.69 |
Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.